LABORATORY ANIMAL PULMONARY DOSING DEVICE

Abstract

A laboratory animal pharmaceutical testing device comprising a substantially closed animal holding cell, having a dry powder generator communicating through a wall of the cell, and one or more filtered inlets for permitting exchange of fresh air into the cell.

Description

BACKGROUND OF THE INVENTION

This invention relates to drug development, and more particularly to improvements in tools for conducting preclinical safety and efficacy studies in animals.

FIELD OF THE INVENTION

Drug development is a time-consuming and costly activity. Procedures are tightly regulated both for safety and to ensure drugs are effective. Of the many compounds studied with the potential to become a medicine, most are eliminated during the initial research phases. Chemical trials follow extensive research using in vitro and animal studies.

Animal studies are a vital part of drug development. Typically, a candidate drug is initially tested in isolated cells, tissue slices or organs. Studies in living animals show whether a drug works the same way inside the body as it did in the artificial environment of the laboratory. They also indicate how the drug effects interactions between different cells and organs of the body. If a potential drug appears to be both safe and effective in animals, it then can be studied in human trials.

Dry powder dosing of animals both for pharmacology and pulmonary toxicology studies are required steps in the development of dry powder inhaled therapies. In order to conduct these studies, dry powder therapeutics need to be aerosolized and delivered to the animals in a controlled, measurable and reproducible manner, and with a prescribed particle size distribution to: 1) screen potential compounds for their efficacy and safety when presented to the animal in a similar manner to humans, and 2) satisfy the FDA that the therapeutic is safe to be tested in man. Current dry powder aerosolization systems, representing state of the art, are relatively rudimentary and inefficient, and as such are highly wasteful of what in many cases is precious amounts of an active pharmaceutical ingredient. Furthermore, these aerosolization systems are certainly not reflective of the ultimate and intended commercial delivery device.

SUMMARY OF THE INVENTION

The present invention provides an improved system for conducting animal tests of active pharmaceutical ingredients. Previously, we have described a unique dry powder inhaler employing a vibratory mechanism for deaggregation and aerosolization of dry powder pharmaceuticals in a dry powder inhaler for delivery of carefully controlled particle size active pharmaceutical ingredients to the lungs of a patient. These same dry powder inhalers also advantageously may be employed to create a “cloud” of active pharmaceutical ingredients in a closed environment for inhalation by animals in preclinical animal testing. Also, these same dry powder inhalers may be used by manually activating the vibratory mechanism to create aerosol clouds in a pulsatile fashion in order to achieve a desirable dose of drug administered over a pre-selected time period or the manual activation may be replaced with automated activation of the aerosolization engine through sensing of the animal's inhalation or tidal breathing maneuver. The closed environment may include, but is not limited to, an animal holding cell or chamber in which the animal is placed inside for full body dosing, or a cell or chamber wherein the animal breathes in from dosing stations on the outside of the chamber, or direct tubing to the animal through a facemask or a nose-only mask or a nasal cannula, e.g. as described in my co-pending U.S. application Ser. No. 12/828,133, based on U.S. Provisional Application Ser. No. 61/222,418, (attorney docket MICRODOSE 09.01 filed contemporaneously herewith, and incorporated herein by reference).

BRIEF DESCRIPTION OF THE DRAWINGS

Further features and advantages of the instant invention will be seen from the following detailed description taken in conjunction with the accompanying drawings, wherein:

FIG. 1 illustrates a laboratory animal full body dosing apparatus in accordance with one embodiment of the present invention;

FIG. 2 illustrates a laboratory animal “nose-only” dosing apparatus in accordance with a second embodiment of the present invention; and

FIG. 3 illustrates yet another embodiment of the invention.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

FIG. 1 illustrates an embodiment of the present invention wherein a pharmaceutical nebulizer 10 communicates through a side wall 12 of an animal holding cell 14. The nebulizer 10 preferably comprises a dry powder nebulizer and communicates via conduit 16 through an opening 18 in side wall 12 that forms an essentially airtight seal. In this embodiment, the opening 18 preferably is located in the upper part of animal holding cell 14 so that a cloud of powdered pharmaceutical will be injected into the upper part of cell 14 and the bulk of the powder will be inhaled by the animal or animals in the cell 14 before the powder settles to the floor of the cell. In a preferred embodiment of the invention, air is recirculated from cell 14 via a conduit 20 and fan 22. In that way, unused medication is returned rather than wasted. If desired, one or more filtered inlets 24 may be provided for permitting introduction of fresh air into the enclosure without permitting escape of any of the powdered pharmaceutical ingredients.

The pharmaceutical nebulizer preferably comprises a vibratory dry powder inhaler available from MicroDose Therapeutx, Inc. of Monmouth Junction, N.J. The dry powder inhaler a high frequency piezo vibrator (see http://mdtx.com/delivery-platforms/dry-powder-inhaler). See also U.S. Pat. Nos. 6,026,809, 6,142,146, 6,152,130, 7,318,434, 7,334,577, 7,343,914 and Published U.S. Application Nos. 2005/0172962 and 2008/0202514, all assigned to the common assignee.

FIG. 2 illustrates an alternative embodiment of the present invention in which laboratory animals are restrained and medication delivered to the animals' nose or mouth. The laboratory animal “nose-only” dosing apparatus includes a dosing chamber 30 including a main chamber 32 and a side chamber 34 opening to animal holding chambers 36. The animal holding chambers 36 are sized to humanely restrain laboratory animals 38 with their mouths and noses 40 held in position in chambers 42 which essentially act as breathing masks. Alternatively, nasal cannulae or mouthpieces may be provided in chambers 42. Chambers 42 (or the nasal cannulae or mouthpieces as the case may be), communicate with side chambers 34 which in turn communicate with main chamber 32. Medication is introduced into main chamber 32 via an opening 44 and the lower end of the main chamber 32 as a cloud of powdered pharmaceutical which is carried to the animals via chambers 42. The cloud is created by sweeping dry powder aerosolized pharmaceutical created at a dry powder aerosol generator 46, and carried by pressurized carrier air stream from a pressurized air source 48. Air pressure is regulated by pressure regulator 50 and an optional flow controller 52.

The apparatus also preferably includes an outlet 54 located adjacent the top end of the dosing chamber 30 leading to a scrubber 56, a dryer 58 and filter 60 and exhaust fan 62 before being vented into the air. In this manner loss of pharmaceutical is minimized, and exposure of laboratory workers to the pharmaceutical is also minimized.

Completing the system is a computer 64 for controlling airflow, duration and frequency of operation of the dry powder aerosol generator, the number of timed or pulsed activations of the vibrating element, etc. The system may also include visual, audible or tactile feedbacks to the equipment operation indicating the status of the device and dosing, etc.

In yet another embodiment of the invention, the nebulizer also may be triggered to turn on and off by sensing tidal breathing of the laboratory animal, and operate over one or several breaths, e.g., following the teachings of our aforesaid co-pending U.S. application Ser. No. 12/828,133, which is incorporated herein by reference. By way of example, as shown in FIGS. 6 and 7 of our aforesaid co-pending application, the inhalation and/or exhalation cycle is sensed and the aerosol generator is turned on for a short duration followed by an amount of chase air to carry or follow the particles into the animal. A sufficient quantity of chase air is necessary to ensure lung deposition when inhalation volumes are low and inhalation cycles are short. Any sensor or combination of sensors that can be used to measure or identify the difference in properties between an inhalation and exhalation maneuver can be used to synchronize and turn the aerosol generator on and off. Examples of sensors that may be used to detect the animals' inhalation/exhalation are flow sensors, pressure sensors, temperature sensors that measure the temperature difference between the inhaled and exhaled breath, carbon dioxide or nitric oxide or other gas sensors that measure the gas component level difference between inhaled and exhaled breath, and also physical measurement systems such as chest straps to measure the expansion and contraction of the chest cavity, etc., can be employed for this purpose. The present invention provides several novel and significant advantages. A feature and advantage of the present invention is that the pharmaceutical nebulizer has an ability to provide greater accuracy, efficiency and reproducibility over current systems. Also, the invention permits delivery of carefully controlled pulmonary drug doses with a targeted and desired particle size distribution. The drug active ingredients may be delivered as a “neat” spray-dried or micronized drug, or lactose blend. Unlike existing laboratory animal testing chambers, laboratory animal testing devices in accordance with the present invention do not require in-line micronizers to maintain a target mass medium aerodynamic particle diameter. Thus, the present invention permits handling of extremely small quantities of drugs, reducing drug waste, and providing more controlled testing environment and greater consistency of dose delivery. Moreover, the systems described are directly reflective of the core system used in hand-held inhalers and dry nebulizers being developed for humans. Thus, administration of dry powder active pharmaceutical ingredients to laboratory animals using vibratory dry powder inhaler technology as described for animal testing more closely mimics delivery of the same active pharmaceutical ingredients in humans. Accordingly, by using essentially the same engine for delivering the dry powder active pharmaceutical ingredients to laboratory test animals as will be used in delivery to humans, scale of delivery through early pharmaceutical studies to toxicity in human trials is more predictable.

Various changes may be made in the above invention without departing from the spirit and scope thereof. For example, it is possible to control the amount of drug delivered to the nasal passages of the laboratory animal as opposed to just the lower respiratory track by controlling particle size. Still other change are possible. For example, referring to FIG. 3, in another embodiment, nebulized drugs may be administered to individual laboratory animal primates via tubing leading to face masks or nasal cannulae, and, if desired, dosing controlled, e.g. by sensing inhalation and exhalation, and turning the nebulizer on and off as described above relative to the other embodiments.

Claims

1. A laboratory animal pharmaceutical testing device comprising a substantially closed animal holding cell, having a pharmaceutical nebulizer communicating through a wall of the cell, and one or more filtered inlets for permitting exchange of fresh air into the cell.

2. The device of claim 1, wherein the nebulizer comprises a vibratory dry powder inhaler.

3. The device of claim 2, wherein the vibrator comprises a piezo vibrator.

4. The device of claim 1, further comprising a microprocessor and control for the nebulizer.

5. The device of claim 1, further comprising a timer for controlling the nebulizer.

6. The device of claim 1, further comprising an electronic controller for controlling airflow equipment connected to the animal holding cell.

7. The device of claim 1, wherein the dose delivered amount is determined by the number of timed or pulsed activations of the nebulizer.

8. The device of claim 1, further comprising visual, audible or tactile feedbacks to the equipment operator indicating the status of the device and of dosing.

9. The device of claim 1, wherein an inhalation and/or exhalation cycle of the animal is sensed, and the nebulizer is turned on and off synchronized to tidal breathing of the animal.

10. The device of claim 9, wherein inhalation and/or exhalation is sensed using sensors selected from the group consisting of flow sensors, pressure sensors, temperature sensors, gas sensors and chest straps.

11. A device for delivering dry powder medication to animals comprising a housing defining an aerosol chamber into which an aerosolized medication may be introduced; an outlet for said chamber;a mask surrounding the outlet, at least in part; anda nebulizer for aerosolizing a medication and introducing the medication into the chamber.

12. The device of claim 11, further comprising a microprocessor and control for the nebulizer.

13. The device of claim 11, further comprising a timer for controlling the nebulizer.

14. The device of claim 11, further comprising an electronic controller for controlling airflow equipment connected to the chamber.

15. The device of claim 11, wherein the dose delivered amount is determined by the number of timed or pulsed activations of the nebulizer.

16. The device of claim 11, further comprising visual, audible or tactile feedbacks to the equipment operator indicating the status of the device and of dosing.

17. The device of claim 11, wherein the mask includes a mouthpiece.

18. The device of claim 11, wherein the mask includes a nasal cannula.

19. The device of claim 11, wherein an inhalation and/or exhalation cycle of the animal is sensed, and the nebulizer is turned on and off synchronized to tidal breathing of the animal.

20. The device of claim 19, wherein inhalation and/or exhalation is sensed using sensors selected from the group consisting of flow sensors, pressure sensors, temperature sensors, gas sensors and chest straps.

21. A laboratory animal pharmaceutical testing device comprising a pharmaceutical nebulizer communicating through tubing to a face mask or nasal cannula, and a controller for controlling the nebulizer.

22. The device of claim 21, wherein the nebulizer comprises a vibratory dry powder inhaler.

23. The device of claim 22, wherein the vibrator comprises a piezo vibrator.

24. The device of claim 21, further comprising a microprocessor and control for the nebulizer.

25. The device of claim 21, wherein the controller comprises a microprocessor.

26. The device of claim 21, further comprising an electronic controller for controlling airflow equipment connected to the nebulizer.

27. The device of claim 21, wherein the dose delivered amount is determined by the number of timed or pulsed activations of the nebulizer.

28. The device of claim 21, further comprising visual, audible or tactile feedbacks to the equipment operator indicating the status of the device and of dosing.

29. The device of claim 21, wherein an inhalation and/or exhalation cycle of the animal is sensed, and the nebulizer is turned on and off synchronized to tidal breathing of the animal.

30. The device of claim 29, wherein inhalation and/or exhalation is sensed using sensors selected from the group consisting of flow sensors, pressure sensors, temperature sensors, gas sensors and chest straps.